Publications

Journal Article
Research Support, U.S. Gov't, P.H.S.
Ppublish 8 citations
Electronic publication date
November 1, 1996

View on Pubmed.gov 8947926 | View on doi.org 10.1007/BF02532...

Use of a mu-antisense oligodeoxynucleotide as a mu opioid receptor noncompetitive antagonist in vivo.

Search for publications in this journal Neurochem Res - 21(11):1363-8

  • X H Chen

    Search for this expert
    1
  • L Y Liu-Chen

    Search for this expert
  • R J Tallarida
  • E B Geller

    Search for this expert
  • J K de Riel

    Search for this expert
  • M W Adler

    Search for this expert

Abstract

We examined whether mu-antisense (AS) oligodeoxynucleotide (oligo) treatment can be used in a manner similar to the mu-selective irreversible antagonist beta-funaltrexamine (beta-FNA) for in vivo pharmacology. Rats were injected intracerebroventricularly (icv) with a mu-AS or a missense (MS) oligo on days 1, 3, 5, 7, and 9 and were tested for the antinociceptive effect of sc injection of morphine on days 2, 4, 6, 8, and 10 in the cold water tail-flick (CWT) test. In another set of experiments, rats were also tested for the antinociceptive action of morphine twenty-four hours after icv injection of beta-FNA. Both beta-FNA and mu-AS produced rightward shifts in the dose-effect curves of morphine. In addition, pretreatment with 2.5 micrograms or more of beta-FNA or the mu-AS oligo for 5-9 days (but not for 1-3 days) reduced the maximal analgesic effect of morphine. The approximate fraction of functional receptor remaining for morphine was determined with the method of Furchgott to be 49.5% following 2.5 micrograms of beta-FNA; that after 5 days of the mu-AS oligo treatment was 50.8%. The results suggest that the mu-AS oligo can be used in the same manner as highly selective, irreversible mu opioid receptor ligands. Thus, properly designed AS oligos against receptors are of particular benefit when irreversible antagonists are not available. AS oligos represent a new class of selective and powerful pharmacological antagonists.

References

J Med Chem. 1980 Mar;23(3):233-4

J Pharmacol Exp Ther. 1982 Jul;222(1):198-201

Pharmacol Biochem Behav. 1986 Jun;24(6):1761-5

J Pharmacol Exp Ther. 1995 Jun;273(3):1047-56

Cited by 8 citations (total)

Journal Article Research Support, N.I.H., Extramural Review

The evolution of vertebrate opioid receptors.

Electronic publication date April 8, 2009

Search for publications in this journal Front Biosci (Landmark Ed)

Craig W Stevens

The proteins that mediate the analgesic and other effects of opioid drugs and endogenous opioid peptides are known as opioid...

Journal Article Research Support, N.I.H., Extramural

Long-Lasting In Vivo Effects of the Cannabinoid CB1 Antagonist AM6538.

Electronic publication date May 29, 2019

Search for publications in this journal J Pharmacol Exp Ther

Carol A Paronis [...] Jack Bergman et al.

AM6538 is a cannabinoid antagonist that binds CB1 receptors expressed in HEK-293 cells in a wash-resistant manner. The effects of...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Substances